VERV - Verve Therapeutics Inc Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Global Select Current Price & Safety Score Price: 11.13 USD StockBonds Safety Grade: D Altman Z-Score (Bankruptcy Risk): 2.35 StockBond Score: 3.75 Company Description Verve Therapeutics Inc a genetic medicines company engages in developing gene editing medicines for patients to treat cardiovascular diseases Its lead product candidate is VERVE101 a singlecourse gene editing treatment that permanently turns off the PCSK9 gene in the liver The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver It has a collaboration and license agreement with Beam Therapeutics Inc a development and option agreement with Acuitas Therapeutics Inc and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College The company was formerly known as Endcadia Inc and changed its name to Verve Therapeutics Inc in January 2019 Verve Therapeutics Inc was incorporated in 2018 and is headquartered in Cambridge Massachusetts